

February 11, 2026

To

BSE Limited,
Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,
Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: OUTCOME OF THE 96TH BOARD MEETING.

Ref: Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held on February 11, 2026, have inter-alia considered and approved the following:

- i. Un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, as recommended by the Audit Committee.**

In this regard, we are enclosing herewith a copy of un-audited (Standalone and Consolidated) financial results for the quarter and nine months ended December 31, 2025 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results.

- ii. Issue of Corporate Guarantee to the tune of ₹20 Crores to RBL Bank on behalf of Subsidiary Company (Mahi Drugs) towards availing of External Commercial Borrowing, subject to shareholders approval.**

In this regard, we are enclosing herewith a report pursuant to sub-para 11 of para "B" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.



iii. Conducting of Postal Ballot by way of remote e-voting facility only, to obtain approval of the shareholders of the Company for Issue of Corporate Guarantee.

Notice of Postal Ballot shall be circulated at a later stage, in compliance with the statutory timelines.

Company will send Postal Ballot Notice by email to all its members who have registered their email addresses with the Company or depository / depository participants and the communication of assent / dissent of the members will only take place through the remote e-voting system.


iv. Outcome of separate meeting of Independent Directors of the Company pursuant to Schedule IV of the Companies Act, 2013 and Regulation 25(3) of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015.

The above information is also available on the website of the Company www.smslife.in

The meeting of the Board commenced at 4.45 pm and concluded at 6.50 pm.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")


Trupti Ranjan Mohanty
Company Secretary



HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Standalone Statement of Un-audited Financial Results for the Quarter and Nine Months Ended 31st December, 2025

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	8,071.91	7,784.35	8,287.65	23,760.54	24,794.33	33,337.10
2	Other Income	7.84	43.64	6.13	147.05	174.60	394.56
3	Total Revenue	8,079.75	7,827.99	8,293.78	23,907.59	24,968.93	33,731.66
4	Expenses						
	(a) Cost of Materials Consumed	3,935.67	4,160.07	4,313.83	11,459.55	12,548.49	16,443.48
	(b) Changes in Inventories	(21.45)	(435.89)	(330.67)	82.81	(116.96)	468.60
	(c) Manufacturing Expenses	1,495.52	1,458.20	1,488.81	4,357.51	4,144.23	5,554.59
	(d) Employee Benefits Expense	1,246.18	1,237.52	1,124.39	3,733.20	3,332.13	4,577.67
	(e) Finance Cost	145.96	150.51	195.57	469.74	603.91	788.07
	(f) Depreciation and Amortization Expense	269.09	268.30	256.35	800.84	763.44	1,025.55
	(g) Other Expenses	260.01	284.50	384.53	802.60	1,022.98	1,869.59
	Total Expenses - (a to g)	7,330.98	7,123.21	7,432.81	21,706.25	22,298.22	30,727.55
5	Profit Before Tax (3-4)	748.77	704.78	860.97	2,201.34	2,670.71	3,004.11
6	Tax Expenses						
	(1) (i) Current Tax	200.00	200.00	250.00	625.00	800.00	900.00
	(ii) Relating to Earlier Year	-	-	(18.87)	-	(18.86)	(18.86)
	(2) Deferred Tax	8.09	7.01	7.09	22.13	20.00	(14.10)
	Total Tax Expenses	208.09	207.01	238.22	647.13	801.14	867.03
7	Net Profit / (Loss) for the Period (5-6)	540.68	497.77	622.75	1,554.21	1,869.57	2,137.08
8	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:						
	Remeasurement of post-employment benefit obligations	1.28	1.23	(18.89)	3.68	(52.30)	4.25
	Income Tax effect on the above	0.37	0.36	(5.50)	1.07	(15.23)	1.24
		0.91	0.87	(13.39)	2.61	(37.07)	3.01
9	Total Comprehensive Income for the period (7+8)	541.59	498.64	609.36	1,556.82	1,832.50	2,140.09
10	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	17.88	16.46	20.60	51.41	61.84	70.69
11	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
12	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						19,415.22

For HALEOS LABS LIMITED

TVVSN Murthy
Managing Director
DIN 00465198

Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 11th February, 2026 and have been approved by the Board of Directors at its meeting held on 11th February, 2026. The Statutory Auditors of the Company have carried out the limited review of Standalone financial results for the quarter and nine months ended 31st December, 2025 and expressed unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company is in compliance with the basic wages criteria as prescribed under New Labour Codes for its employees and also for contract workforce. In view of this and based on the best information available and consistent with the guidance issued by the Institute of Chartered Accountants of India, the management is of the view, that no further provision is required.

Once the Central/State Rules are notified by the Government on all aspects of the New Labour Codes, the Company will evaluate impact, if any, on the measurement of the employee benefits and would provide appropriate accounting effect on the basis of such development as needed.

The Company continues to monitor the finalisation of the Central and State Rules and will incorporate appropriate accounting treatment, required if any, as and when such developments are notified.
- 4 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

For HALEOS LABS LIMITED

TVVSN Murthy
Managing Director
DIN 00465198

Place: Hyderabad
Date : 11-02-2026



Independent Auditor's Review Report on the Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

**Review Report to
The Board of Directors
Haleos Labs Limited
(Formerly known as SMS Lifesciences India Limited)**

We have reviewed the accompanying statement of unaudited standalone financial results of **Haleos Labs Limited** (Formerly known as **SMS Lifesciences India Limited**) ("the Company"), for the quarter and nine months ended 31st December 2025 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 11.02.2026

UDIN:26026548XIQKPC6454

For Rambabu & Co.,
Chartered Accountants
Reg. No.0029765


GVL Prasad
Partner
M.No. 026548



HALEOS LABS LIMITED
(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Consolidated Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2025

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	9,478.31	8,136.76	8,460.10	25,865.54	25,561.11	34,472.35
2	Other Income	18.34	42.41	5.74	150.38	252.07	486.01
3	Total Revenue	9,496.65	8,179.17	8,465.84	26,015.92	25,813.18	34,958.36
4	Expenses						
	(a) Cost of Materials Consumed	4,473.90	3,983.27	3,943.18	11,298.55	11,716.78	14,990.79
	(b) Changes in Inventories	(111.86)	(881.39)	(383.58)	(320.68)	(247.96)	415.21
	(c) Manufacturing Expenses	1,752.02	1,732.08	1,757.54	5,134.56	4,860.52	6,555.05
	(d) Employee Benefits Expense	1,669.65	1,622.84	1,460.14	4,921.66	4,306.81	5,953.78
	(e) Finance Cost	154.43	161.53	213.79	502.48	667.83	871.26
	(f) Depreciation and Amortization Expense	390.99	388.63	375.69	1,162.00	1,119.83	1,499.67
	(g) Other Expenses	289.75	322.96	407.37	888.27	1,163.23	2,053.61
	Total Expenses - (a to g)	8,618.88	7,329.92	7,774.13	23,586.84	23,587.04	32,339.37
5	Profit Before Tax (3-4)	877.77	849.25	691.71	2,429.08	2,226.14	2,618.99
6	Tax Expenses						
	(1) (i) Current Tax	201.00	215.00	250.00	656.00	800.00	900.00
	(ii) Relating to Earlier Year	-	-	-	-	(18.86)	(18.86)
	(2) Mat Credit Entitlement	(1.00)	(15.00)	(18.87)	(31.00)	-	-
	(3) Deferred Tax	12.88	6.72	(24.73)	58.45	(79.96)	(135.39)
		212.88	206.72	206.40	683.45	701.17	745.75
7	Net Profit / (Loss) for the Period / Year (5-6)	664.89	642.53	485.31	1,745.63	1,524.96	1,873.24
8	Other Comprehensive Income/(Loss) (OCI): Items that will not be reclassified to statement of Profit & Loss Remeasurement of post-employment benefit obligations	5.82	5.35	(20.80)	16.08	(57.53)	17.87
	Income Tax effect on the above	(1.55)	(1.43)	5.99	(4.29)	16.59	(4.78)
		4.27	3.92	(14.81)	11.79	(40.94)	13.09
9	Total comprehensive Income for the period/year (7+8)	669.16	646.45	470.50	1,757.42	1,484.02	1,886.33
10	Profit for the year attributable to:						
	Equity holders of the parent	661.68	610.26	546.55	1,687.63	1,713.62	2,010.90
	Non-controlling interest	3.21	32.27	(61.24)	58.00	(188.65)	(137.66)
11	Total comprehensive income for the year attributable to:						
	Equity holders of the parent	664.61	612.96	532.31	1,695.75	1,674.22	2,019.96
	Non-controlling interest	4.55	33.49	(61.81)	61.67	(190.20)	(133.63)
12	Earning Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	21.89	20.19	18.08	55.82	56.68	66.51
13	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
14	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						19,353.70

For HALEOS LABS LIMITED

TVSN Murthy
Managing Director
DIN 00465198

Notes:

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 11th February, 2026 and have been approved by the Board of Directors at its meeting held on 11th February, 2026. The Statutory Auditors of the Company have carried out the limited review of Consolidated financial results for the quarter and half year ended 31st December, 2025 and expressed unmodified opinion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Group is in compliance with the basic wages criteria as prescribed under New Labour Codes for its employees and also for contract workforce. In view of this and based on the best information available and consistent with the guidance issued by the Institute of Chartered Accountants of India, the management is of the view, that no further provision is required.

Once the Central/State Rules are notified by the Government on all aspects of the New Labour Codes, the Group will evaluate impact, if any, on the measurement of the employee benefits and would provide appropriate accounting effect on the basis of such development as needed.

The Group continues to monitor the finalisation of the Central and State Rules and will incorporate appropriate accounting treatment, required if any, as and when such developments are notified.

- 4 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary.
- 5 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

For HALEOS LABS LIMITED

TVVSU Murthy
Managing Director
DIN 00465198

Place: Hyderabad
Date : 11-02-2026



Independent Auditor's Review Report on review of Interim Consolidated Financial Results

To the Board of Directors of
Haleos Labs Limited
(Formerly known as SMS Lifesciences India Limited)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **Haleos Labs Limited** (formerly known as **SMS Lifesciences India Limited**) ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter and nine months ended 31st December, 2025 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities
- M/s. Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited)
 - M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.1,734.01 Lakhs, total net profit after tax of Rs.8.03 Lakhs and total comprehensive gain of Rs.11.38 Lakhs & total revenue of Rs.4,221.29 Lakhs, total net profit after tax of Rs.145.00 Lakhs and total comprehensive gain of Rs.154.18 Lakhs for the Quarter and nine months ended 31st December, 2025, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad
Date: 11.02.2026

UDIN:26026548RBKPPC3546

For Rambabu & Co.,
Chartered Accountants
Reg. No.002976S


GVL Prasad
Partner
M. No. 026548



Details of Corporate Guarantee:

[as specified in SEBI Master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Sl. no.	Particulars	Information
1.	Name of party for which such guarantee or indemnity or surety was given	Mahi Drugs Private Limited (Subsidiary with 60% stake)
2.	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Promoter / Promoter Group / Group Companies do not have any direct interest in this transaction. <u>Mahi Drugs is material subsidiary of the Company.</u> Corporate Guarantee has been issued on an arm's length basis.
3.	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	Extend the Corporate Guarantee to RBL Bank to secure the External Commercial Borrowings (ECB) facility of ₹20 Crores being sanctioned to its subsidiary company.
4.	Impact of such guarantees or indemnity or surety on listed entity	Corporate Guarantee provided is a contingent liability for the Company. This guarantee has been provided on behalf of the material Subsidiary of the Company whose accounts is consolidated with the accounts of the Company. At this point, there is no impact of this guarantee on the Company.



February 11, 2026

To

BSE Limited,
Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,
Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: OUTCOME OF SEPARATE MEETING OF INDEPENDENT DIRECTORS OF THE COMPANY.

Dear Sir/Madam,

In continuation to our intimation dated February 4, 2026, we wish to inform that pursuant to Schedule IV of the Companies Act, 2013 and Regulation 25(3) of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015, a Separate Meeting of the Independent Directors was held on February 11, 2026 and transacted the following businesses:

- i. Reviewed the performance of Non- Independent Directors and the Board as a whole;
- ii. Assessed the quality, quantity and timeliness of the flow of information between the Company's management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

Independent Directors evaluated the performance of the Board of Directors of the Company and found the results are "**satisfactory**". Whereas the Company does not have a full-time Chairman, the requirement of evaluation of the performance of the Chairman of the Company, was not applicable.

Please take the same on record and suitably disseminate it to all concerned.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")

Sarath Kumar Pakalapati

Independent Director

DIN: 01456746



Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)